• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Clopidogrel, Aspirin and Proton Pump Inhibition after Percutaneous Valve Implants: An Update.
Conclusions: TAVR is a new technology that compresses a tissue valve onto an expandable stent. Technical and procedural issues have been solved, but strokes and major bleeding still affect patients' life despite double antiplatelet therapy given to reduce MACCE. To balance pros and cons, antithrombotic therapy with Warfarin or new anticoagulants can be used in patients with previous AF or NOAF to prevent stroke; while single antiplatelet with PPI is a better alternative in patients with liver disease, gastric ulcer or drug abuse to avoid bleeding events. While waiting for randomized trials, a tailored therapy based upon ph...
Source: Current Pharmaceutical Design - December 4, 2012 Category: Drugs & Pharmacology Authors: Fusari M Tags: Curr Pharm Des Source Type: research

Peri-procedural anticoagulation in catheter ablation for atrial fibrillation: a review.
Abstract Catheter ablation for rhythm control in atrial fibrillation has been recognized as an established treatment. Patients with atrial fibrillation suffer from an increased risk from thromboembolic events. Long-term stroke risk and mortality has been shown to be reduced after catheter ablation, still the procedure per se is associated with an additive peri-procedural thromboembolic risk. Maintenance of the thrombotic - bleeding equilibrium in such patients during interventional procedures is compelling. Lack of data from randomized studies along with the recent introduction of novel oral anticoagulants in clin...
Source: Current Pharmaceutical Design - December 4, 2016 Category: Drugs & Pharmacology Authors: Vrachatis DA, Giannopoulos G, Kossyvakis C, Vasiliki P, Vavuranakis M, Papaioannou TG, Pagoni S, Pyrgakis VN, Cleman MW, Deftereos SG Tags: Curr Pharm Des Source Type: research

Impact of pre-procedural cerebrovascular events on clinical outcomes after transcatheter aortic valve implantation in patients with severe aortic stenosis.
CONCLUSION: We showed that a history of CVEs in patients with severe AS undergoing TAVI is associated with a higher long-term mortality. PMID: 29468958 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - February 19, 2018 Category: Drugs & Pharmacology Authors: Wiktorowicz A, Kleczynski P, Dziewierz A, Tokarek T, Sorysz D, Bagienski M, Rzeszutko L, Dudek D Tags: Curr Pharm Des Source Type: research

Effects of ABCB1 genotypes on the pharmacokinetics and clinical outcomes of new oral anticoagulants: A systematic review and meta-analysis.
Conclusions Cmax was lower in carriers of ABCB1 rs1045642 CC than in those of TT and in carriers of rs2032582 GG than in those of the A/T allele, and AUC0-∞ was lower in carriers of rs1045642 CC than in those of TT. Conversely, ABCB1 rs4148738 genotypes did not affect primary clinical endpoints in dabigatran-administered patients. Future studies should analyze the relationships of ABCB1 genotypes with the pharmacokinetics and clinical outcomes of specific NOACs. PMID: 30338730 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - October 18, 2018 Category: Drugs & Pharmacology Authors: Xie Q, Xiang Q, Mu G, Ma L, Chen S, Zhou S, Hu K, Zhang Z, Cui Y, Jian J Tags: Curr Pharm Des Source Type: research

Novel Oral Anticoagulants in Peripheral Artery Disease. Current Evidence.
CONCLUSION: For the time being, novel oral anticoagulants in combination with aspirin may provide an alternative treatment in PAD, however, it is deemed necessary to identify patient subgroups who will benefit the most. PMID: 30585539 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - December 26, 2018 Category: Drugs & Pharmacology Authors: Koutsoumpelis A, Argyriou C, Tasopoulou KM, Georgakarakos EI, Georgiadis GS Tags: Curr Pharm Des Source Type: research

Direct oral anticoagulants compared with vitamin K antagonists for left ventricular thrombus: a systematic review and meta-analysis
CONCLUSION: DOACs and VKAs showed no difference in the safety and efficacy of patients with LVT. DOACs might be superior to VKAs for LVT treatment in post-AMI patients.PMID:35400334 | DOI:10.2174/1381612828666220408120832
Source: Current Pharmaceutical Design - April 11, 2022 Category: Drugs & Pharmacology Authors: Shu Fang Bao-Zhen Zhu Fan Yang Zhe Wang Qian Xiang Yan-Jun Gong Source Type: research

Pages: 1  2